3-(1-OXO-4-((4-((3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)METHYL)BENZYL) OXY)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | 1323403-73-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-(1-OXO-4-((4-((3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)METHYL)BENZYL) OXY)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
• 英文别名: 3-(1-oxo-4-((4-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione；3-[3-oxo-7-[[4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]phenyl]methoxy]-1H-isoindol-2-yl]piperidine-2,6-dione
• CAS: 1323403-73-1
• 化学式: C₂₇H₂₅F₃N₆O₄
• 分子量: 554.529
• InChiKey: GNYDHMZFCDSZQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxoisoindolin-2-yl]piperidine-2,6-dione 、 3-三氟甲基-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪盐酸盐 在 N,N-二异丙基乙胺 、 四丁基氟化铵 作用下， 以 乙腈 为溶剂， 以48%的产率得到3-(1-OXO-4-((4-((3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)METHYL)BENZYL) OXY)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
  参考文献：
  名称：

  Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same

  摘要：

  提供了4'-芳基甲氧基异吲哚啉化合物，以及其药用盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。

  公开号：

  US20110196150A1

文献信息

• ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：Celgene Corporation

  公开号：US20180037567A1

  公开（公告）日：2018-02-08

  Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了4'-芳基甲氧基异吲哚啉化合物及其药学上可接受的盐、溶剂合物、笼合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。
• METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES
  申请人：Celgene Corporation

  公开号：EP3925609A1

  公开（公告）日：2021-12-22

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of pomalidomide with an anti-CSl antibody.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括服用泊马度胺和抗-CSl抗体。
• Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
  申请人：Celgene Corporation

  公开号：US10034872B2

  公开（公告）日：2018-07-31

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括在接受了自体干细胞移植的患者中使用免疫调节化合物，如来那度胺或泊马度胺与抗CS1抗体，如艾洛妥珠单抗。
• Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
  申请人：Celgene Corporation

  公开号：US10189814B2

  公开（公告）日：2019-01-29

  Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本发明提供了 4′-芳基甲氧基异吲哚啉化合物及其药学上可接受的盐、溶液剂、凝胶体、立体异构体和原药。还公开了这些化合物的使用方法和药物组合物。
• METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20140314752A1

  公开（公告）日：2014-10-23

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.